93 results
S-3ASR
DAWN
Day One Biopharmaceuticals, Inc.
28 Aug 24
Automatic shelf registration
4:07pm
through a publication in Nature Medicine.
The approval of OJEMDA was based, in part, on the major efficacy outcome measure of overall response rate
8-K
EX-10.1
DAWN
Day One Biopharmaceuticals, Inc.
30 Jul 24
Day One Announces Oversubscribed $175.0 Million Private Placement
7:04am
to the Investor’s obligations set forth in Section 6.1 below are satisfied (other than those conditions
which, by their nature, are to be satisfied … included in any “forward-looking statements” disclaimer or any other statements that are similarly predictive or forward-looking in nature
8-K
EX-99.1
z3zo54u5plciu6umz
25 Jul 24
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
6:04am
8-K
EX-99.1
crb6vx1yyfx42jat7e
12 Jun 24
Regulation FD Disclosure
8:07am
8-K
EX-99.2
51z6zcfk
30 May 24
Day One Announces Sale of Priority Review Voucher for $108 Million
8:35am
8-K
EX-99.2
09cyu1aiesta z3tx6
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
kalca
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.1
y63ia3 lr3ayg1c
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
poqad
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.1
54ab7eruqqjd
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
ypx775orer5y 2h3ul8
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.1
9ofi3pe8
8 Jan 24
Regulation FD Disclosure
8:30am
8-K
EX-99.2
req7r2md3
8 Jan 24
Regulation FD Disclosure
8:30am